The Digitalis Investigation Group Trial
In the Digitalis Investigation Group trial, 7,788 individuals with chronic HF were randomly assigned to receive digoxin or placebo. Most of these persons were already receiving an ACEI and a diuretic. Of the 7,788 participants, 6,800 had systolic HF and were enrolled in the main trial and followed up for a median of 37 months. Digoxin had no effect on mortality among those with systolic HF (relative risk [RR] 0.99, 95% confidence interval [CI] 0.91-1.07) but reduced hospitalization resulting from worsening HF (RR 0.72, 95% CI 0.66-0.79). Among individuals with diastolic HF enrolled in the ancillary trial, digoxin had similar effects: no influence on mortality (RR 0.99, 95% CI 0.76-1.28) but a reduction in hospitalization due to worsening HF (RR 0.79, 95% CI 0.59-1.04). This latter association was not statistically significant, likely due to the small sample size in the DIG ancillary trial.
Geriatrics and Aging. 2008;11(1):37-41. © 2008 1453987 Ontario, Ltd.
Cite this: An Update on the Role of Digoxin in Older Adults with Chronic Heart Failure - Medscape - Jan 01, 2008.